SA’s progress in expanding access to PrEP is one of the few positive findings in the latest global AIDS report.

Research into desperately needed new tuberculosis (TB) drugs is flagging because governments and pharmaceutical companies are not investing enough in the field, scientists warned on the eve of the 21st International AIDS conference, which begins on Monday (July 18).

30 November 2015 - Investing in the fight against tuberculosis (TB) offers potentially huge future savings, with an estimated return of $85 for every dollar spent.

The Medicines Control Council has approved Janssen Pharmaceutica’s bedaquiline, the first drug specifically designed for treating multidrug-resistant tuberculosis (MDR-TB) to reach the market.

SOUTHERN African countries could realise savings 40 times what they would otherwise spend if they were to test and treat all mineworkers in the gold and platinum group metal industries for tuberculosis (TB), according to the preliminary findings of a World Bank study released on Tuesday.

The government’s policy on intellectual property (IP), currently under discussion, would seek to strike a balance between the needs of public health and the interests of innovative pharmaceutical companies, Trade and Industry Minister Rob Davies said on Tuesday.

TUBERCULOSIS (TB) is a disease most people associate with poverty or HIV/AIDS. Not so, says the head of the University of Cape Town’s Institute of Infectious Disease and Molecular Medicine, Valerie Mizrahi, who has first-hand experience of just how easily it can sweep through a middle-class family.

The Executive Director of the advocacy group Section27 has taken issue with the "rosy picture" the United Nations joint agency on HIV/AIDS (UNAIDS) has painted of the world’s response to HIV, saying the end of the epidemic was nowhere nigh.

CAPE TOWN — QdotPharma, the only South African-owned clinical research organisation able to do "first in man" drug studies, has closed its doors, citing delays in project approvals by the Medicines Control Council (MCC).

South African drug development company iThemba Pharmaceuticals has devised a cheaper way to make the widely used AIDS drug tenofovir and had identified several promising treatments for tuberculosis (TB), Emory University’s Prof Dennis Liotta said yesterday.